Pf-08098488

Phase 1

Pfizer

Pf-08098488 is one of 48 therapeutic programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pancreatic Ductal AdenocarcinomaRecruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

94 competitors in Pancreatic Ductal Adenocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

37 2

Abraxane

Bristol-Myers Squibb

Phase 3

29 3

Eloxatin

Teva

Phase 3

13 4

Camptosar

Pfizer

Phase 3

9 5

Adrucil

EElorac, Inc.

Phase 3

7 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

5 7

5-Fluorouracil

Merck & Co.

Phase 3

2 8

Opdivo

Bristol-Myers Squibb

Phase 2

5 9

Keytruda

Merck & Co.

Phase 2

5 10

Folinic Acid

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 1Recruiting

Pancreatic Ductal Adenocarcinoma

NCT07903415

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

A PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08098488 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS.

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07903415·280 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pf-08098488. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Pf-08098488. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Pfizer

Pf-08098488

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News